IL155775A0 - Treatment of male sexual dysfunction - Google Patents

Treatment of male sexual dysfunction

Info

Publication number
IL155775A0
IL155775A0 IL15577501A IL15577501A IL155775A0 IL 155775 A0 IL155775 A0 IL 155775A0 IL 15577501 A IL15577501 A IL 15577501A IL 15577501 A IL15577501 A IL 15577501A IL 155775 A0 IL155775 A0 IL 155775A0
Authority
IL
Israel
Prior art keywords
treatment
sexual dysfunction
male sexual
male
dysfunction
Prior art date
Application number
IL15577501A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0030647A external-priority patent/GB0030647D0/en
Priority claimed from GB0108730A external-priority patent/GB0108730D0/en
Priority claimed from GB0109910A external-priority patent/GB0109910D0/en
Priority claimed from GB0111037A external-priority patent/GB0111037D0/en
Priority claimed from US09/895,367 external-priority patent/US20020028799A1/en
Priority claimed from US09/905,846 external-priority patent/US6878529B2/en
Priority claimed from GB0120679A external-priority patent/GB0120679D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of IL155775A0 publication Critical patent/IL155775A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/344—Disorders of the penis and the scrotum and erectile dysfuncrion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL15577501A 2000-12-15 2001-12-10 Treatment of male sexual dysfunction IL155775A0 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB0030647A GB0030647D0 (en) 2000-12-15 2000-12-15 Treatment of male sexual dysfunction
GB0108730A GB0108730D0 (en) 2001-04-06 2001-04-06 Treatment of male sexual dysfunction
GB0109910A GB0109910D0 (en) 2001-04-23 2001-04-23 Treatment of sexual dysfunction
GB0111037A GB0111037D0 (en) 2001-05-04 2001-05-04 Treatment of sexual dysfunction
US09/895,367 US20020028799A1 (en) 2000-07-06 2001-06-29 Treatment of male sexual dysfunction
US09/905,846 US6878529B2 (en) 2000-07-14 2001-07-13 Compounds for the treatment of sexual dysfunction
GB0120679A GB0120679D0 (en) 2001-08-24 2001-08-24 Treatment of male sexual dysfunction
PCT/IB2001/002399 WO2002047670A1 (fr) 2000-12-15 2001-12-10 Traitement du dysfonctionnement sexuel male

Publications (1)

Publication Number Publication Date
IL155775A0 true IL155775A0 (en) 2003-12-23

Family

ID=27562581

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15577501A IL155775A0 (en) 2000-12-15 2001-12-10 Treatment of male sexual dysfunction

Country Status (9)

Country Link
EP (1) EP1347750A1 (fr)
JP (1) JP2004522720A (fr)
CN (1) CN1496254A (fr)
AU (1) AU2002220977A1 (fr)
CA (1) CA2431747A1 (fr)
HU (1) HUP0400528A2 (fr)
IL (1) IL155775A0 (fr)
NZ (1) NZ526925A (fr)
WO (1) WO2002047670A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60040089D1 (de) 1999-11-19 2008-10-09 Solvay Pharm Bv Menschliches homolog aus der familie der metalloproteasen
JP2005504043A (ja) 2001-08-10 2005-02-10 パラチン テクノロジーズ インク． 生物学的に活性な金属ペプチド類のペプチド模倣体類
WO2005000217A2 (fr) * 2003-06-06 2005-01-06 Merck & Co., Inc. Polytherapie permettant de traiter la dyslipidemie
EP1925307A1 (fr) * 2006-11-03 2008-05-28 Emotional Brain B.V. Utilisation de 3-alpha-androstanediol pour le traitement des dysfonctions sexuelles
US8101371B2 (en) 2007-10-18 2012-01-24 Musc Foundation For Research Development Methods for the diagnosis of genitourinary cancer
DE102009018668A1 (de) 2009-04-23 2010-11-25 Igor Lier Faltbare Duschkabine
ES2776734T3 (es) * 2010-11-15 2020-07-31 Neuroderm Ltd Administración continua de L-dopa, inhibidores de dopa descarboxilasa, inhibidores de catecol-o-metil transferasa y composiciones para ello
CN111840508A (zh) * 2020-07-17 2020-10-30 北京清大赛尔生物科技有限公司 一种预防及治疗男性性功能障碍的外用制剂及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052890A1 (fr) * 1997-05-21 1998-11-26 Eli Lilly And Company Antagonistes du recepteur des 3-arylpropylamino neuropeptides y
IL139454A0 (en) * 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
US6458790B2 (en) * 2000-03-23 2002-10-01 Merck & Co., Inc. Substituted piperidines as melanocortin receptor agonists
WO2001085173A1 (fr) * 2000-05-10 2001-11-15 Bristol-Myers Squibb Company Derives d'alkylamine d'antagonistes de dihydropyridine npy
US6432960B2 (en) * 2000-05-10 2002-08-13 Bristol-Myers Squibb Company Squarate derivatives of dihydropyridine NPY antagonists
US6444675B2 (en) * 2000-05-10 2002-09-03 Bristol-Myers Squibb Company 4-alkyl and 4-cycloalkyl derivatives of dihydropyridine NPY antagonists

Also Published As

Publication number Publication date
CA2431747A1 (fr) 2002-06-20
HUP0400528A2 (hu) 2004-06-28
CN1496254A (zh) 2004-05-12
WO2002047670A1 (fr) 2002-06-20
AU2002220977A1 (en) 2002-06-24
NZ526925A (en) 2005-03-24
EP1347750A1 (fr) 2003-10-01
JP2004522720A (ja) 2004-07-29

Similar Documents

Publication Publication Date Title
IL153492A0 (en) Treatment of male sexual dysfunction
IL137569A0 (en) Treatment of female sexual dysfunction
EP1027057A4 (fr) Traitement du dysfonctionnement sexuel chez la femme
GB0225908D0 (en) Treatment of female sexual dysfunction
IL155775A0 (en) Treatment of male sexual dysfunction
IL154642A0 (en) Treatment of urinary dysfunction
PL362980A1 (en) Treatment of sexual dysfunction
GB0130219D0 (en) Compounds for the treatment of sexual dysfunction
GB2386555B (en) Treatment of female sexual dysfunction
IL166273A0 (en) Methods of treatment of male erectile dysfunction
AU8906201A (en) Methods and compositions for the treatment and prevention of sexual dysfunction
GB0030647D0 (en) Treatment of male sexual dysfunction
GB0120679D0 (en) Treatment of male sexual dysfunction
GB0108483D0 (en) Treatment of male sexual dysfunction
GB0108730D0 (en) Treatment of male sexual dysfunction
GB0106167D0 (en) Treatment of male sexual dysfunction
IL155814A0 (en) Treatment of sexual dysfunction using bombesin antagonist
GB0011926D0 (en) Treatment of sexual dysfunction
IL162822A0 (en) Treatment of male sexual dysfunction
AU2001281396A1 (en) Novel compositions and methods for treatment of male erectile dysfunction
GB0126904D0 (en) Treatment of sexual dysfunction
GB0109910D0 (en) Treatment of sexual dysfunction
GB0111037D0 (en) Treatment of sexual dysfunction
GB9928178D0 (en) Agent for the treatment of male and female sexual dysfunction
AU2002219246A1 (en) Methof for treatment of female sexual dysfunction